Purinergic signalling in cancer therapeutic resistance: From mechanisms to targeting strategies

被引：11
作者：
Jia, Wenhui [1 ,2 ,3 ,4 ]
Huang, Zhao [1 ,2 ,3 ,4 ]
Zhou, Li [5 ]
Liou, Yih-Cherng [6 ,7 ]
Di Virgilio, Francesco [8 ]
Ulrich, Henning [9 ,10 ]
Illes, Peter [9 ,11 ]
Zhang, Wei [12 ,13 ,14 ]
Huang, Canhua [1 ,2 ,3 ,4 ,15 ]
Tang, Yong [9 ,16 ,17 ]
机构：
[1] West China Hosp, Canc Ctr, Dept Biotherapy, Chengdu 610041, Peoples R China
[2] West China Hosp, State Key Lab Biotherapy, Chengdu 610041, Peoples R China
[3] Sichuan Univ, West China Sch Basic Med Sci & Forens Med, Chengdu 610041, Peoples R China
[4] Collaborat Innovat Ctr Biotherapy, Chengdu 610041, Peoples R China
[5] Chongqing Med Univ, Affiliated Hosp 2, Inst Viral Hepatitis, Dept Infect Dis,Key Lab Mol Biol Infect Dis,Minist, Chongqing 400016, Peoples R China
[6] Natl Univ Singapore, NUS Grad Sch Integrat Sci & Engn, Singapore 117573, Singapore
[7] Natl Univ Singapore, Fac Sci, Dept Biol Sci, 14 Sci Dr 4, Singapore 117573, Singapore
[8] Univ Ferrara, Dept Med Sci, Ferrara, Italy
[9] Chengdu Univ Tradit Chinese Med, Int Joint Res Ctr Purinerg Signalling, Chengdu 610075, Peoples R China
[10] Univ Sao Paulo, Inst Chem, Dept Biochem, Sao Paulo, Brazil
[11] Univ Leipzig, Rudolf Boehm Inst Pharmakol & Toxikol, Leipzig, Germany
[12] Sichuan Univ, Mental Hlth Ctr, Chengdu 610041, Peoples R China
[13] Sichuan Univ, West China Hosp, Psychiat Lab, State Key Lab Biotherapy, Chengdu 610041, Peoples R China
[14] Sichuan Univ, West China Hosp, West China Biomed Big Data Ctr, Chengdu 610041, Peoples R China
[15] Chengdu Univ Tradit Chinese Med, Inst TCM Based Stress Med, Chengdu 611137, Peoples R China
[16] Chengdu Univ Tradit Chinese Med, Sch Hlth & Rehabil, Chengdu 610075, Peoples R China
[17] Chengdu Univ Tradit Chinese Med, Acupuncture & Chronobiol Key Lab Sichuan Prov, Chengdu 610075, Peoples R China
来源：
DRUG RESISTANCE UPDATES | 2023年 / 70卷
基金：
巴西圣保罗研究基金会;
关键词：
Purinergic signalling; Cancer; Therapeutic resistance; Targeted therapy; RECEPTOR ANTAGONIST; EXTRACELLULAR ATP; DELIVERY-SYSTEMS; IN-VIVO; CELLS; IMMUNOSUPPRESSION; MICROENVIRONMENT; EXPRESSION; CARCINOMA; MIGRATION;
D O I：
10.1016/j.drup.2023.100988
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Purinergic signalling, consisting of extracellular purines and purinergic receptors, modulates cell proliferation, invasion and immunological reaction during cancer progression. Here, we focus on current evidence that suggests the crucial role of purinergic signalling in mediating cancer therapeutic resistance, the major obstacle in cancer treatment. Mechanistically, purinergic signalling can modulate the tumor microenvironment (TME), epithelial-mesenchymal transition (EMT) and anti-tumor immunity, thus affecting drug sensitivity of tumor cells. Currently, some agents attempting to target purinergic signalling either in tumor cells or in tumor-associated immune cells are under preclinical or clinical investigation. Moreover, nano-based delivery technologies significantly improve the efficacy of agents targeting purinergic signalling. In this review article, we summarize the mechanisms of purinergic signalling in promoting cancer therapeutic resistance and discuss the potentials and challenges of targeting purinergic signalling in future cancer treatment.
引用
收藏
页数：13
相关论文
共 139 条
  • [1] Expression of P2X7 Receptor Increases In Vivo Tumor Growth
    Adinolfi, Elena
    Raffaghello, Lizzia
    Giuliani, Anna Lisa
    Cavazzini, Luigi
    Capece, Marina
    Chiozzi, Paola
    Bianchi, Giovanna
    Kroemer, Guido
    Pistoia, Vito
    Di Virgilio, Francesco
    [J]. CANCER RESEARCH, 2012, 72 (12) : 2957 - 2969
  • [2] Nano-therapeutics for modulating the tumour microenvironment: Design, development, and clinical translation
    Adityan, Siddharth
    Tran, Michelle
    Bhavsar, Chintan
    Wu, Sherry Y.
    [J]. JOURNAL OF CONTROLLED RELEASE, 2020, 327 : 512 - 532
  • [3] Simultaneous inhibition of CD73 and IL-6 molecules by siRNA-loaded nanoparticles prevents the growth and spread of cancer
    Allahyari, Sima Emadi
    Hajizadeh, Farnaz
    Zekiy, Angelina Olegovna
    Mansouri, Niloofar
    Gilan, Parisa Sahami
    Mousavi, Seyedeh Mahboubeh
    Masjedi, Ali
    Hassannia, Hadi
    Ahmadi, Majid
    Mohammadi, Hamed
    Yousefi, Mehdi
    Izadi, Sepideh
    Zolbanin, Naime Majidi
    Jafari, Reza
    Jadidi-Niaragh, Farhad
    [J]. NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE, 2021, 34
  • [4] MRI-traceable theranostic nanoparticles for targeted cancer treatment
    Anani, Tareq
    Rahmati, Shiva
    Sultana, Nayer
    David, Allan E.
    [J]. THERANOSTICS, 2021, 11 (02): : 579 - 601
  • [5] [Anonymous], 2021, Cancer Discov, V11, pOF4, DOI 10.1158/2159-8290.CD-NB2021-0313
  • [6] Targeting the A2A adenosine receptor counteracts immunosuppression in vivo in a mouse model of chronic lymphocytic leukemia
    Arruga, Francesca
    Serra, Sara
    Vitale, Nicoletta
    Guerra, Giulia
    Papait, Andrea
    Gyau, Benjamin Baffour
    Tito, Francesco
    Efremov, Dimitar
    Vaisitti, Tiziana
    Deaglio, Silvia
    [J]. HAEMATOLOGICA, 2021, 106 (05) : 1343 - 1353
  • [7] Quiescent cancer cells resist T cell attack by forming an immunosuppressive niche
    Baldominos, Pilar
    Barbera-Mourelle, Alex
    Barreiro, Olga
    Huang, Yu
    Wight, Andrew
    Cho, Jae-Won
    Zhao, Xi
    Estivill, Guillem
    Adam, Isam
    Sanchez, Xavier
    McCarthy, Shannon
    Schaller, Julien
    Khan, Zara
    Ruzo, Albert
    Pastorello, Ricardo
    Richardson, Edward T.
    Dillon, Deborah
    Montero-Llopis, Paula
    Barroso-Sousa, Romualdo
    Forman, Juliet
    Shukla, Sachet A.
    Tolaney, Sara M.
    Mittendorf, Elizabeth A.
    von Andrian, Ulrich H.
    Wucherpfennig, Kai W.
    Hemberg, Martin
    Agudo, Judith
    [J]. CELL, 2022, 185 (10) : 1694 - +
  • [8] Group Behavior and Emergence of Cancer Drug Resistance
    Bhattacharya, Supriyo
    Mohanty, Atish
    Achuthan, Srisairam
    Kotnala, Sourabh
    Jolly, Mohit Kumar
    Kulkarni, Prakash
    Salgia, Ravi
    [J]. TRENDS IN CANCER, 2021, 7 (04): : 323 - 334
  • [9] DIVERSITY AND BIOLOGY OF CANCER-ASSOCIATED FIBROBLASTS
    Biffi, Giulia
    Tuveson, David A.
    [J]. PHYSIOLOGICAL REVIEWS, 2021, 101 (01) : 147 - 176
  • [10] Adenosine Metabolism: Emerging Concepts for Cancer Therapy
    Boison, Detlev
    Yegutkin, Gennady G.
    [J]. CANCER CELL, 2019, 36 (06) : 582 - 596
12345678910